Log in

NASDAQ:PHASPhaseBio Pharmaceuticals Stock Price, Forecast & News

$6.01
-0.01 (-0.17 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.51
Now: $6.01
$6.09
50-Day Range
$3.28
MA: $4.17
$6.02
52-Week Range
$2.60
Now: $6.01
$14.08
Volume1.87 million shs
Average Volume1.45 million shs
Market Capitalization$172.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. The company has an agreement with Viamet Pharmaceuticals Holdings, LLC and Selenity Pharmaceuticals (Bermuda) Ltd. to develop PB6440, a lead development compound for treatment of resistant hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHAS
CUSIPN/A
CIKN/A
Phone610-981-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.36 million
Book Value$1.86 per share

Profitability

Net Income$-39,250,000.00
Net Margins-2,310.60%

Miscellaneous

Employees40
Market Cap$172.97 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive PHAS News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAS and its competitors with MarketBeat's FREE daily newsletter.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions

How has PhaseBio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PHAS shares have increased by 92.0% and is now trading at $6.01. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PhaseBio Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PhaseBio Pharmaceuticals.

When is PhaseBio Pharmaceuticals' next earnings date?

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for PhaseBio Pharmaceuticals.

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) announced its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.10. The business earned $0.32 million during the quarter, compared to analysts' expectations of $0.38 million. PhaseBio Pharmaceuticals had a negative return on equity of 70.50% and a negative net margin of 2,310.60%. View PhaseBio Pharmaceuticals' earnings history.

What price target have analysts set for PHAS?

6 equities research analysts have issued 12 month target prices for PhaseBio Pharmaceuticals' stock. Their forecasts range from $4.00 to $18.00. On average, they anticipate PhaseBio Pharmaceuticals' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 116.3% from the stock's current price. View analysts' price targets for PhaseBio Pharmaceuticals.

Has PhaseBio Pharmaceuticals been receiving favorable news coverage?

News articles about PHAS stock have trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PhaseBio Pharmaceuticals earned a daily sentiment score of -3.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutPhaseBio Pharmaceuticals.

Are investors shorting PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 2,490,000 shares, a drop of 10.1% from the April 15th total of 2,770,000 shares. Based on an average trading volume of 277,500 shares, the short-interest ratio is presently 9.0 days. Currently, 17.9% of the shares of the company are short sold. View PhaseBio Pharmaceuticals' Current Options Chain.

Who are some of PhaseBio Pharmaceuticals' key competitors?

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Amarin (AMRN), Viking Therapeutics (VKTX), VBI Vaccines (VBIV), TapImmune (MRKR), Selecta Biosciences (SELB), Zynerba Pharmaceuticals (ZYNE) and Dynavax Technologies (DVAX).

Who are PhaseBio Pharmaceuticals' key executives?

PhaseBio Pharmaceuticals' management team includes the following people:
  • Mr. Jonathan P. Mow, Pres, CEO & Director (Age 55, Pay $678.78k)
  • Mr. John P. Sharp, Chief Financial Officer (Age 55, Pay $548.51k)
  • Dr. John S. Lee, Chief Medical Officer (Age 52, Pay $581.5k)
  • Mr. Kristopher L. Hanson, VP, Head of Legal & Corp. Sec. (Age 48)
  • Mr. Michael B. York, VP of Corp. Devel. & Commercial Strategy (Age 55)

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an initial public offering on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel served as the underwriters for the IPO and Needham was co-manager.

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

Who are PhaseBio Pharmaceuticals' major shareholders?

PhaseBio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (13.99%), BlackRock Inc. (3.44%), Ghost Tree Capital LLC (1.73%), DAFNA Capital Management LLC (1.11%), State Street Corp (0.87%) and Geode Capital Management LLC (0.75%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson and Venture Advisors Iii Hatteras. View institutional ownership trends for PhaseBio Pharmaceuticals.

Which major investors are selling PhaseBio Pharmaceuticals stock?

PHAS stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC, Morgan Stanley, BlackRock Inc., UBS Group AG, and First Trust Advisors LP. View insider buying and selling activity for PhaseBio Pharmaceuticals.

Which major investors are buying PhaseBio Pharmaceuticals stock?

PHAS stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Ghost Tree Capital LLC, Geode Capital Management LLC, State Street Corp, Sabby Management LLC, Wells Fargo & Company MN, Bank of New York Mellon Corp, and Nuveen Asset Management LLC. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson, and Venture Advisors Iii Hatteras. View insider buying and selling activity for PhaseBio Pharmaceuticals.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $6.01.

How big of a company is PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals has a market capitalization of $172.97 million and generates $2.36 million in revenue each year. The company earns $-39,250,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. PhaseBio Pharmaceuticals employs 40 workers across the globe.

What is PhaseBio Pharmaceuticals' official website?

The official website for PhaseBio Pharmaceuticals is www.phasebio.com.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.